比索洛尔治疗慢性阻塞性肺疾病急性发作的远期预后观察

目的:探讨比索洛尔治疗慢性阻塞性肺疾病急性发作的远期预后观察。方法:选取2013年1月~2014年1月某院收治的慢性阻塞性肺疾病急性发作患者300例,根据治疗方式的不同分为研究组(150例)与对照组(150例),对照组予常规治疗,研究组在对照组的基础上联合比索洛尔治疗,比较两组治疗前后肺功能指标(第1s用力呼气容积(FEV1)、用力肺活量(FVC)、第1s用力呼气容积占预计值百分比(FEV1/FVC));炎症因子(外周血肿瘤坏死因子-a(TNF-a)、白介素-6(IL-6))与慢性阻塞性肺疾病急性发作的次数与因心律失常导致猝死的发生率。结果:治疗前两组肺功能指标、炎症因子水平、急性发作的次数无明显差异(P>0.05),两组患者治疗结束时与治疗后12个月、5年后的肺功能指标均明显高于治疗前,研究组治疗结束时与治疗后12个月、5年后的FEV1、FVC、FEV1/FVC均显著高于对照(P<0.05);治疗结束时与治疗后12个月、5年后研究组的CRP、TNF-a均明显低于对照组(P<0.05),研究组治疗结束时与治疗后12个月、5年后的炎症因子水平无显著差异(P>0.05);治疗后研究组急性发作次数与猝死率显著低于对照组(P<0.05)。结论:在慢性阻塞性肺疾病急性发作的治疗中采用比索洛尔,可有效改善患者的肺功能,提高免疫力,缓解炎症反应,有利于患者恢复,在治疗后急性发作的次数可明显减少,猝死发生减少,远期预后效果良好,具有较高的临床价值。

Long Term Prognosis of Bisoprolol in the Treatment of Acute Attack of COPD

Objective:To investigate the long-term prognosis of bisoprolol in the treatment of acute attack of COPD.Methods:From January 2013 to January 2014,300 patients with acute attack of chronic obstructive pulmonary disease in a hospital were selected and divided into study group(150 cases)and control group(150 cases)according to the different treatment methods.The control group was treated with routine treatment,the study group was treated with bisoprolol on the basis of the control group,and the lung function indexes(FEV1,FVC,FEV1/FVC),inflammatory factors(TNF-a,IL-6)and the frequency of acute attack of chronic obstructive pulmonary disease and the incidence of sudden death due to arrhythmia before and after the treatment in the two groups were compared.Results:There was no significant difference in lung function indexes,inflammatory factors levels and acute attack frequency between the two groups before treatment(P>0.05).The lung function indexes of the two groups at the end of treatment and 12 months and 5 years after treatment were significantly higher than those before treatment.The FEV1,FVC and FEV1/FVC of the study group at the end of treatment and 12 months and 5 years after treatment were significantly higher than those of the control group(P<0.05).After 12 months and 5 years of treatment,CRP and TNF-a in the study group were significantly lower than those in the control group(P<0.05).There was no significant difference in the level of inflammatory factors in the study group at the end of treatment and 12 months and 5 years after treatment(P>0.05).The number of acute attacks and sudden death rate in the study group after treatment were significantly lower than those in the control group(P<0.05).Conclusion:The application of bisoprolol in the treatment of acute episode of chronic obstructive pulmonary disease can effectively improve the lung function,improve the immunity,alleviate the inflammatory response,and help the recovery of patients.After treatment,the number of acute episodes can be significantly reduced,the incidence of sudden death is reduced,and the long-term prognosis is good,with high clinical value.